Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/3720833

Documents

In Collections

This item can be found in the following collections:

Tüchler, A.; Pauw, A. de; Ernst, C.; Anota, A.; Lakeman, I.M.M.; Dick, J.; ... ; Hahnen, E. (2024)

Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction

Article / Letter to editor
Background: Breast cancer (BC) risk prediction models consider cancer family history (FH) and germline pathogenic variants (PVs) in risk genes. It remains elusive to what extent complementation with polygenic risk score (PRS) and non-genetic risk factor (NGRFs) data affects individual intensified breast surveillance (IBS) recommendations according to European guidelines.Methods: For 425 cancer-free women with cancer FH (mean age 40.6 years, range 21-74), recruited in France, Germany and the Netherlands, germline PV status, NGRFs, and a 306 variant-based PRS (PRS306) were assessed to calculate estimated lifetime risks (eLTR) and estimated 10-year risks (e10YR) using CanRisk. The proportions of women changing country-specific European risk categories for IBS recommendations, i.e. >= 20 % and >= 30 % eLTR, or >= 5 % e10YR were determined.Findings: Of the women with non-informative PV status, including PRS306 and NGRFs changed clinical recommendations for 31.0 %, (57/184, 20 % eLTR), 15...Show moreBackground: Breast cancer (BC) risk prediction models consider cancer family history (FH) and germline pathogenic variants (PVs) in risk genes. It remains elusive to what extent complementation with polygenic risk score (PRS) and non-genetic risk factor (NGRFs) data affects individual intensified breast surveillance (IBS) recommendations according to European guidelines.Methods: For 425 cancer-free women with cancer FH (mean age 40.6 years, range 21-74), recruited in France, Germany and the Netherlands, germline PV status, NGRFs, and a 306 variant-based PRS (PRS306) were assessed to calculate estimated lifetime risks (eLTR) and estimated 10-year risks (e10YR) using CanRisk. The proportions of women changing country-specific European risk categories for IBS recommendations, i.e. >= 20 % and >= 30 % eLTR, or >= 5 % e10YR were determined.Findings: Of the women with non-informative PV status, including PRS306 and NGRFs changed clinical recommendations for 31.0 %, (57/184, 20 % eLTR), 15.8 % (29/184, 30 % eLTR) and 22.4 % (41/183, 5 % e10YR), respectively whereas of the women tested negative for a PV observed in their family, clinical recommendations changed for 16.7 % (25/150), 1.3 % (2/150) and 9.5 % (14/147). No change was observed for 82 women with PVs in high-risk genes (BRCA1/2 , PALB2). Combined consideration of eLTRs and e10YRs identified BRCA1/2 PV carriers benefitting from IBS <30 years, and women tested non-informative/negative for whom IBS may be postponed. Interpretation: For women who tested non-informative/negative, PRS and NGRFs have a considerable impact on IBS recommendations. Combined consideration of eLTRs and e10YRs allows personalizing IBS starting age.Funding: Horizon 2020, German Cancer Aid, Federal Ministry of Education and Research, Koln Fortune.Show less
Breast cancer
Genetic testing
Hereditary breast and ovarian cancer syndrome
Cancer prevention
All authors
Tüchler, A.; Pauw, A. de; Ernst, C.; Anota, A.; Lakeman, I.M.M.; Dick, J.; Stoep, N. van der; Asperen, C.J. van; Maringa, M.; Herold, N.; Blümcke, B.; Remy, R.; Westerhoff, A.; Stommel-Jenner, D.J.; Frouin, E.; Richters, L.; Golmard, L.; Kütting, N.; Colas, C.; Wappenschmidt, B.; Rhiem, K.; Devilee, P.; Stoppa-Lyonnet, D.; Schmutzler, R.K.; Hahnen, E.
Date
2024-02-01
Journal
The Breast
Volume
73
DOI
doi:10.1016/j.breast.2023.103615